Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Euromed's Milk Thistle Extract Shown in New Study to Helping to Reduce Inflammatory Activity in Human Liver and Immune Cells
  • USA - English


News provided by

Euromed USA

Mar 01, 2017, 04:00 ET

Share this article

Share toX

Share this article

Share toX

PhytoProof, To BE SURE
PhytoProof, To BE SURE

Presto, PA (PRWEB) March 01, 2017 -- With the February 3rd publication of this study, good health news is here for all those who suffer from inflammation, which is the root cause of a wide variety of health conditions. The study indicates that by using the pure high quality Milk Thistle extract from Euromed it may be possible to regulate inflammation by its actions of altering cellular metabolism and inhibiting inflammatory activity in human liver and immune cells.

We here at Euromed, the world's leading manufacturer of milk thistle extract, are very excited that this new study opens the door to an emerging health benefit, that of counteracting pro-inflammatory conditions.

Post this

The study, entitled “Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells,” was written by Erica S. Lovelace , et al. Here is the link to the complete study online: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171139 This research was conducted by the University of Washington, and was supported under a grant from the National Center for Complementary and Integrative Health (NCCIH).

Chronic Inflammation: Winning the Battle
Inflammation is the body’s natural response to all kinds of environmental threats: germs, toxins, environmental pollutants, injury, stress, a variety of microorganisms, and other harmful influences. The process involves immune, vascular, and cellular biochemical reactions which work to remove the offenders and protect tissues from damage. On a basic level, this natural defense mode works to shield the body’s systems and initiate the healing process. However, when people experience a chronic state of inflammation, it can have serious effects on the body’s cellular health, and has been linked to numerous degenerative diseases.

Immune activation causes production of substances that stimulate migration of circulating white blood cells to go to the site of inflammation. When persistent exposure to microorganisms exists, a state of dysregulated inflammation can occur, establishing a state of chronic immune activation that can potentially lead to a variety of health issues. In this study, Euromed’s milk thistle extract (Powdered extract of the seeds (achenes) of Silybum marianum [L.] Gaertn) elicits broad anti-inflammatory and immune-regulating activity in primary human immune cells from both normal people and those individuals with HIV.

World Leader of Milk Thistle Extract: Euromed, Barcelona, Spain
Euromed’s milk thistle extract was specifically selected for use in this study because of the fact that they are the world’s leading manufacturer of milk thistle extract. The company was established in 1971 for manufacturing the milk thistle extract to be used for the pharmaceutical product, Legalon® marketed by Madaus A.G. in Germany. Euromed has established cultivation of Silybum marianum seeds in 3 countries in Europe using its proprietary cultivar of “elite seeds.” The firm has complete traceability from the seed to the finished extract following its Phyto-Proof® process of quality control. This includes a minimum of 20 laboratory tests from the starting seed to the finished extract. Its milk thistle extract contains a full complement of all 6 silymarin isomers -- in the proper ratio for bioactivity -- as referenced in the US and European Pharmacopeia Official Milk Thistle Extract Monographs.

“We are very excited that this new study opens the door to an emerging health benefit of Euromed’s milk thistle extract, that of counteracting pro-inflammatory conditions present in some individuals,” stated Guy Woodman, General Manager for Euromed USA.

Dietary supplement users consuming milk thistle extract for its protective liver and antioxidant benefits may also benefit from its suppression of inflammatory metabolic pathways. “Euromed’s milk thistle extract offers promise to individuals experiencing dysregulation of normal inflammation due to chronic exposure to environmental agents,” according to Pilar Pais, Ph.D. Technical Director of Euromed S.A.

ABOUT EUROMED
Euromed supplies standardized botanical and herbal extracts and natural active substances for use in the dietary supplement, pharmaceutical, and cosmetics industries. By concentrating phytochemicals nature has provided, the company can guarantee that each batch of its extracts meets the same profile documented in clinical studies to be safe and effective. Euromed was founded 46 years ago; the company was recently acquired by The Riverside Company, with its US offices located in Presto, Pennsylvania. For additional information about Euromed’s extracts, call 412-279-8808 or email BeSure(at)EuromedUSA.com and visit http://www.EuromedUSA.com

Guy Woodman, Euromed USA, http://www.euromedUSA.com, +1 831-588-8767, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.